Therapeutic targeting of autophagy in cancer. Part II: Pharmacological modulation of treatment-induced autophagy

Seminars in Cancer Biology

Volumn 31, Issue , 2015, Pages 99-105

  Nagelkerke, Anika ^a   Bussink, Johan ^a   Geurts Moespot, Anneke ^a   Sweep, Fred C G J ^a   Span, Paul N ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Autophagy; Cancer; Inducer; Inhibitor; Therapy

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 3 METHYLADENINE; 4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANTINEOPLASTIC AGENT; BAFILOMYCIN; BECLIN 1; C6 CERAMIDE; CETUXIMAB; CHLOROQUINE; CISPLATIN; DACTOLISIB; DAPORINAD; DASATINIB; DEOXYGLUCOSE; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN; SPAUTIN 1; TAMOXIFEN; TEMOZOLOMIDE; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; AUTOPHAGOSOME; AUTOPHAGY; BECLIN1 GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER THERAPY; CARCINOGENESIS; CELL DEATH; CELL PROTECTION; CHAPERONE-MEDIATED AUTOPHAGY; CYTOPLASMIC DEGRADATION; CYTOSTASIS; CYTOTOXICITY; DEGRADATION; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME DEGRADATION; GENE SILENCING; HUMAN; IMMUNOMODULATION; MACROAUTOPHAGY; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; RADIOSENSITIVITY; REVIEW; TREATMENT OUTCOME; UPREGULATION; BIOLOGICAL MODEL; CELL AGING; DRUG EFFECTS; NEOPLASMS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CELL AGING; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84923257166     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2014.06.001     Document Type: Review

References (94)

1. Apel A., Herr I., Schwarz H., Rodemann H.P., Mayer A. Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Res 2008, 68:1485-1494.
2. Bursch W., Ellinger A., Kienzl H., Torok L., Pandey S., Sikorska M., et al. Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy. Carcinogenesis 1996, 17:1595-1607.
3. Chaachouay H., Ohneseit P., Toulany M., Kehlbach R., Multhoff G., Rodemann H.P. Autophagy contributes to resistance of tumor cells to ionizing radiation. Radiother Oncol 2011, 99:287-292.
4. Cufi S., Vazquez-Martin A., Oliveras-Ferraros C., Corominas-Faja B., Cuyas E., Lopez-Bonet E., et al. The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer. Sci Rep 2013, 3:2469.
5. Hu C., Solomon V.R., Ulibarri G., Lee H. The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine. Bioorg Med Chem 2008, 16:7888-7893.
6. Li X., Fan Z. The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex. Cancer Res 2010, 70:5942-5952.
7. Li X., Lu Y., Pan T., Fan Z. Roles of autophagy in cetuximab-mediated cancer therapy against EGFR. Autophagy 2010, 6:1066-1077.
8. Li Y.Y., Lam S.K., Mak J.C., Zheng C.Y., Ho J.C. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer. Lung Cancer 2013, 81:354-361.
9. Paglin S., Hollister T., Delohery T., Hackett N., McMahill M., Sphicas E., et al. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res 2001, 61:439-444.
10. Paglin S., Lee N.Y., Nakar C., Fitzgerald M., Plotkin J., Deuel B., et al. Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells. Cancer Res 2005, 65:11061-11070.
11. Qadir M.A., Kwok B., Dragowska W.H., To K.H., Le D., Bally M.B., et al. Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization. Breast Cancer Res Treat 2008, 112:389-403.
12. Samaddar J.S., Gaddy V.T., Duplantier J., Thandavan S.P., Shah M., Smith M.J., et al. A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance. Mol Cancer Ther 2008, 7:2977-2987.
13. Vazquez-Martin A., Oliveras-Ferraros C., Menendez J.A. Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. PLoS One 2009, 4:e6251.
14. Zou Y., Ling Y.H., Sironi J., Schwartz E.L., Perez-Soler R., Piperdi B. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib. J Thorac Oncol 2013, 8:693-702.
15. Klionsky D.J., Emr S.D. Autophagy as a regulated pathway of cellular degradation. Science 2000, 290:1717-1721.
16. Kroemer G., Marino G., Levine B. Autophagy and the integrated stress response. Mol Cell 2010, 40:280-293.
17. Levine B., Klionsky D.J. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 2004, 6:463-477.
18. Mizushima N., Ohsumi Y., Yoshimori T. Autophagosome formation in mammalian cells. Cell Struct Funct 2002, 27:421-429.
19. Rebecca V.W., Massaro R.R., Fedorenko I.V., Sondak V.K., Anderson A.R., Kim E., et al. Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma. Pigment Cell Melanoma Res 2014.
20. Seront E., Boidot R., Bouzin C., Karroum O., Jordan B.F., Gallez B., et al. Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours. Br J Cancer 2013, 109:2597-2606.
21. Granville C.A., Warfel N., Tsurutani J., Hollander M.C., Robertson M., Fox S.D., et al. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clin Cancer Res 2007, 13:2281-2289.
22. Kuwahara Y., Oikawa T., Ochiai Y., Roudkenar M.H., Fukumoto M., Shimura T., et al. Enhancement of autophagy is a potential modality for tumors refractory to radiotherapy. Cell Death Dis 2011, 2:e177.
23. Albert J.M., Kim K.W., Cao C., Lu B. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther 2006, 5:1183-1189.
24. Cao C., Subhawong T., Albert J.M., Kim K.W., Geng L., Sekhar K.R., et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 2006, 66:10040-10047.
25. Nam H.Y., Han M.W., Chang H.W., Lee Y.S., Lee M., Lee H.J., et al. Radioresistant cancer cells can be conditioned to enter senescence by mTOR inhibition. Cancer Res 2013, 73:4267-4277.
26. Pool S.E., Bison S., Koelewijn S.J., van der Graaf L.M., Melis M., Krenning E.P., et al. mTOR Inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer. Cancer Res 2012, 73:12-18.
27. Ji D., Zhang Z., Cheng L., Chang J., Wang S., Zheng B., et al. The combination of RAD001 and MK-2206 exerts synergistic cytotoxic effects against PTEN mutant gastric cancer cells: involvement of MAPK-dependent autophagic, but not apoptotic cell death pathway. PLoS One 2014, 9:e85116.
28. Wang X., Yue P., Kim Y.A., Fu H., Khuri F.R., Sun S.Y. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res 2008, 68:7409-7418.
29. Jeong E.H., Choi H.S., Lee T.G., Kim H.R., Kim C.H. Dual Inhibition of PI3K/Akt/mTOR pathway and role of autophagy in non-small cell lung cancer cells. Tuberc Respir Dis (Seoul) 2012, 72:343-351.
30. Neri L.M., Cani A., Martelli A.M., Simioni C., Junghanss C., Tabellini G., et al. Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. Leukemia 2013.
31. Memmott R.M., Mercado J.R., Maier C.R., Kawabata S., Fox S.D., Dennis P.A. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila) 2010, 3:1066-1076.
32. Liu H., Scholz C., Zang C., Schefe J.H., Habbel P., Regierer A.C., et al. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res 2012, 32:1627-1637.
33. Ben Sahra I., Laurent K., Giuliano S., Larbret F., Ponzio G., Gounon P., et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 2010, 70:2465-2475.
34. Zannella V.E., Dal Pra A., Muaddi H., McKee T.D., Stapleton S., Sykes J., et al. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin Cancer Res 2013, 19:6741-6750.
35. Harhaji-Trajkovic L., Vilimanovich U., Kravic-Stevovic T., Bumbasirevic V., Trajkovic V. AMPK-mediated autophagy inhibits apoptosis in cisplatin-treated tumour cells. J Cell Mol Med 2009, 13:3644-3654.
36. Janjetovic K., Harhaji-Trajkovic L., Misirkic-Marjanovic M., Vucicevic L., Stevanovic D., Zogovic N., et al. In vitro and in vivo anti-melanoma action of metformin. Eur J Pharmacol 2011, 668:373-382.
37. Mizushima N., Yoshimori T., Levine B. Methods in mammalian autophagy research. Cell 2010, 140:313-326.
38. Jones S.A., Mills K.H., Harris J. Autophagy and inflammatory diseases. Immunol Cell Biol 2013, 91:250-258.
39. Liu J., Xia H., Kim M., Xu L., Li Y., Zhang L., et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell 2011, 147:223-234.
40. Correa R.J., Valdes Y.R., Peart T.M., Fazio E.N., Bertrand M., McGee J., et al. Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability. Carcinogenesis 2014.
41. Shao S., Li S., Qin Y., Wang X., Yang Y., Bai H., et al. Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia. Int J Oncol 2014.
42. Xie R., Nguyen S., McKeehan W.L., Liu L. Acetylated microtubules are required for fusion of autophagosomes with lysosomes. BMC Cell Biol 2010, 11:89.
43. Settembre C., Zoncu R., Medina D.L., Vetrini F., Erdin S., Huynh T., et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J 2012, 31:1095-1108.
44. Jiang P.D., Zhao Y.L., Deng X.Q., Mao Y.Q., Shi W., Tang Q.Q., et al. Antitumor and antimetastatic activities of chloroquine diphosphate in a murine model of breast cancer. Biomed Pharmacother 2010, 64:609-614.
45. Jiang P.D., Zhao Y.L., Shi W., Deng X.Q., Xie G., Mao Y.Q., et al. Cell growth inhibition, G2/M cell cycle arrest, and apoptosis induced by chloroquine in human breast cancer cell line Bcap-37. Cell Physiol Biochem. 2008, 22:431-440.
46. Zhou Q., McCracken M.A., Strobl J.S. Control of mammary tumor cell growth in vitro by novel cell differentiation and apoptosis agents. Breast Cancer Res Treat 2002, 75:107-117.
47. Tuomela J., Sandholm J., Kauppila J.H., Lehenkari P., Harris K.W., Selander K.S. Chloroquine has tumor-inhibitory and tumor-promoting effects in triple-negative breast cancer. Oncol Lett 2013, 6:1665-1672.
48. Loehberg C.R., Thompson T., Kastan M.B., Maclean K.H., Edwards D.G., Kittrell F.S., et al. Ataxia telangiectasia-mutated and p53 are potential mediators of chloroquine-induced resistance to mammary carcinogenesis. Cancer Res 2007, 67:12026-12033.
49. Rahim R., Strobl J.S. Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells. Anticancer Drugs 2009, 20:736-745.
50. Chen N., Karantza V. Autophagy as a therapeutic target in cancer. Cancer Biol Ther 2011, 11:157-168.
51. Chen S., Rehman S.K., Zhang W., Wen A., Yao L., Zhang J. Autophagy is a therapeutic target in anticancer drug resistance. Biochim Biophys Acta 2010, 1806:220-229.
52. Goldberg S.B., Supko J.G., Neal J.W., Muzikansky A., Digumarthy S., Fidias P., et al. A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. J Thorac Oncol 2012, 7:1602-1608.
53. Sotelo J., Briceno E., Lopez-Gonzalez M.A. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006, 144:337-343.
54. Kim K.W., Moretti L., Mitchell L.R., Jung D.K., Lu B. Endoplasmic reticulum stress mediates radiation-induced autophagy by perk-eIF2alpha in caspase-3/7-deficient cells. Oncogene 2010, 29:3241-3251.
55. Nagelkerke A., Bussink J., van der Kogel A.J., Sweep F.C., Span P.N. The PERK/ATF4/LAMP3-arm of the unfolded protein response affects radioresistance by interfering with the DNA damage response. Radiother Oncol 2013, 108:415-421.
56. Kim S.H., Kim J.H., Fried J. Enhancement of the radiation response of cultured tumor cells by chloroquine. Cancer 1973, 32:536-540.
57. Ratikan J.A., Sayre J.W., Schaue D. Chloroquine engages the immune system to eradicate irradiated breast tumors in mice. Int J Radiat Oncol Biol Phys 2013, 87:761-768.
58. Ko A., Kanehisa A., Martins I., Senovilla L., Chargari C., Dugue D., et al. Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling. Cell Death Differ 2014, 21:92-99.
59. Rouschop K.M., van den Beucken T., Dubois L., Niessen H., Bussink J., Savelkouls K., et al. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J Clin Invest 2010, 120:127-141.
60. Song J., Qu Z., Guo X., Zhao Q., Zhao X., Gao L., et al. Hypoxia-induced autophagy contributes to the chemoresistance of hepatocellular carcinoma cells. Autophagy 2009, 5:1131-1144.
61. Shoemaker J.P. Fifty-five percent complete remission of mammary carcinoma in mice with 5-fluorouracil and chloroquine. Cancer Res 1978, 38:2700-2702.
62. Li J., Hou N., Faried A., Tsutsumi S., Kuwano H. Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model. Eur J Cancer 2010, 46:1900-1909.
63. O'Donovan T.R., O'Sullivan G.C., McKenna S.L. Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics. Autophagy 2011, 7:509-524.
64. Nagelkerke A., Sieuwerts A.M., Bussink J., Sweep C.G., Look M.P., Foekens J.A., et al. LAMP3 is involved in tamoxifen resistance in breast cancer through modulation of autophagy. Endocr Relat Cancer 2014.
65. Kohli L., Kaza N., Coric T., Byer S.J., Brossier N.M., Klocke B.J., et al. 4-Hydroxytamoxifen induces autophagic death through K-Ras degradation. Cancer Res 2013, 73:4395-4405.
66. Hou Q., Jin J., Zhou H., Novgorodov S.A., Bielawska A., Szulc Z.M., et al. Mitochondrially targeted ceramides preferentially promote autophagy, retard cell growth, and induce apoptosis. J Lipid Res 2011, 52:278-288.
67. Daido S., Kanzawa T., Yamamoto A., Takeuchi H., Kondo Y., Kondo S. Pivotal role of the cell death factor BNIP3 in ceramide-induced autophagic cell death in malignant glioma cells. Cancer Res 2004, 64:4286-4293.
68. Travelli C., Drago V., Maldi E., Kaludercic N., Galli U., Boldorini R., et al. Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etoposide or cisplatin in neuroblastoma cells. J Pharmacol Exp Ther 2011, 338:829-840.
69. Shingu T., Fujiwara K., Bogler O., Akiyama Y., Moritake K., Shinojima N., et al. Inhibition of autophagy at a late stage enhances imatinib-induced cytotoxicity in human malignant glioma cells. Int J Cancer 2009, 124:1060-1071.
70. Kanzawa T., Germano I.M., Komata T., Ito H., Kondo Y., Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 2004, 11:448-457.
71. Schafranek L., Leclercq T.M., White D.L., Hughes T.P. Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy. Leuk Lymphoma 2013, 54:198-201.
72. Adiseshaiah P.P., Clogston J.D., McLeland C.B., Rodriguez J., Potter T.M., Neun B.W., et al. Synergistic combination therapy with nanoliposomal C6-ceramide and vinblastine is associated with autophagy dysfunction in hepatocarcinoma and colorectal cancer models. Cancer Lett 2013, 337:254-265.
73. Kon M., Kiffin R., Koga H., Chapochnick J., Macian F., Varticovski L., et al. Chaperone-mediated autophagy is required for tumor growth. Sci Transl Med 2011, 3:109ra17.
74. Finn P.F., Mesires N.T., Vine M., Dice J.F. Effects of small molecules on chaperone-mediated autophagy. Autophagy 2005, 1:141-145.
75. Cheng Y., Zhang Y., Zhang L., Ren X., Huber-Keener K.J., Liu X., et al. MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol Cancer Ther 2012, 11:154-164.
76. Josset E., Burckel H., Noel G., Bischoff P. The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line. Anticancer Res 2013, 33:1845-1851.
77. Choi E.J., Cho B.J., Lee D.J., Hwang Y.H., Chun S.H., Kim H.H., et al. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases. BMC Cancer 2014, 14:17.
78. Cerniglia G.J., Karar J., Tyagi S., Christofidou-Solomidou M., Rengan R., Koumenis C., et al. Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Mol Pharmacol 2012, 82:1230-1240.
79. Komatsu S., Moriya S., Che X.F., Yokoyama T., Kohno N., Miyazawa K. Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells. Biochem Biophys Res Commun 2013, 437:41-47.
80. Moriya S., Che X.F., Komatsu S., Abe A., Kawaguchi T., Gotoh A., et al. Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells. Int J Oncol 2013, 42:1541-1550.
81. Rahmani M., Aust M.M., Attkisson E., Williams D.C., Ferreira-Gonzalez A., Grant S. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood 2012, 119:6089-6098.
82. Pan J., Cheng C., Verstovsek S., Chen Q., Jin Y., Cao Q. The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells. Cancer Lett 2010, 293:167-174.
83. Wei Y., Kadia T., Tong W., Zhang M., Jia Y., Yang H., et al. The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clin Cancer Res 2010, 16:3923-3932.
84. Tang Y., Hamed H.A., Cruickshanks N., Fisher P.B., Grant S., Dent P. Obatoclax and lapatinib interact to induce toxic autophagy through NOXA. Mol Pharmacol 2012, 81:527-540.
85. Lee Y.J., Won A.J., Lee J., Jung J.H., Yoon S., Lee B.M., et al. Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells. Int J Med Sci 2012, 9:881-893.
86. Dupere-Richer D., Kinal M., Menasche V., Nielsen T.H., Del Rincon S., Pettersson F., et al. Vorinostat-induced autophagy switches from a death-promoting to a cytoprotective signal to drive acquired resistance. Cell Death Dis 2013, 4:e486.
87. Michaud M., Martins I., Sukkurwala A.Q., Adjemian S., Ma Y., Pellegatti P., et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011, 334:1573-1577.
88. Panaretakis T., Kepp O., Brockmeier U., Tesniere A., Bjorklund A.C., Chapman D.C., et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009, 28:578-590.
89. Roninson I.B. Tumor cell senescence in cancer treatment. Cancer Res 2003, 63:2705-2715.
90. Young A.R., Narita M., Ferreira M., Kirschner K., Sadaie M., Darot J.F., et al. Autophagy mediates the mitotic senescence transition. Genes Dev 2009, 23:798-803.
91. Knizhnik A.V., Roos W.P., Nikolova T., Quiros S., Tomaszowski K.H., Christmann M., et al. Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage. PLoS One 2013, 8:e55665.
92. Gewirtz D.A. Autophagy and senescence in cancer therapy. J Cell Physiol 2014, 229:6-9.
93. Kang H.T., Lee K.B., Kim S.Y., Choi H.R., Park S.C. Autophagy impairment induces premature senescence in primary human fibroblasts. PLoS One 2011, 6:e23367.
94. Klionsky D.J., Abdalla F.C., Abeliovich H., Abraham R.T., Acevedo-Arozena A., Adeli K., et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012, 8:445-544.